Eisai Inc. to Pull Epilepsy Drug From Germany
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Japanese drugmaker Eisai is to stop selling its new epilepsy therapy Fycompa in Germany - the biggest market for the product - following a row over the price it can charge for the drug. The case highlights the growing battle-lines between drug companies and healthcare providers in Europe, where governments are taking a tough line on social spending at a time of economic austerity. Germany's new system for determining drug prices is a particular point of friction because it requires manufacturers to demonstrate that new medicines work better than older ones before they can charge a premium. The German system was implemented in 2010 as part of a drug pricing law designed to save billions of euros.
Help employers find you! Check out all the jobs and post your resume.
Japanese drugmaker Eisai is to stop selling its new epilepsy therapy Fycompa in Germany - the biggest market for the product - following a row over the price it can charge for the drug. The case highlights the growing battle-lines between drug companies and healthcare providers in Europe, where governments are taking a tough line on social spending at a time of economic austerity. Germany's new system for determining drug prices is a particular point of friction because it requires manufacturers to demonstrate that new medicines work better than older ones before they can charge a premium. The German system was implemented in 2010 as part of a drug pricing law designed to save billions of euros.
Help employers find you! Check out all the jobs and post your resume.